MedTrace Logo

Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

NCT00456716 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2010-03-04

No results posted yet for this study

Summary

Open label study of sorafenib

Conditions

Interventions

DRUG

sorafenib

400mg po bid

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Amgen

    collaborator INDUSTRY

  • Swedish Medical Center

    lead OTHER

Principal Investigators

  • Howard J West, M.D. · Swedish Cancer Institute

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-03-31
Primary Completion
2008-12-31
Completion
2008-12-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00456716 on ClinicalTrials.gov